Prestige Consumer Healthcare (NYSE:PBH) Shares Gap Up – Should You Buy?

Prestige Consumer Healthcare Inc. (NYSE:PBH)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $66.52, but opened at $68.99. Prestige Consumer Healthcare shares last traded at $69.50, with a volume of 15,256 shares trading hands.

Analyst Upgrades and Downgrades

PBH has been the subject of a number of analyst reports. Jefferies Financial Group reduced their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Finally, Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and an average price target of $80.60.

Prestige Consumer Healthcare Trading Up 0.8%

The company has a 50 day moving average of $64.50 and a 200 day moving average of $63.40. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of 18.41, a P/E/G ratio of 2.19 and a beta of 0.43.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). The business had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same period last year, the firm earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insider Activity

In other news, VP Jeffrey Zerillo sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the sale, the vice president directly owned 41,048 shares in the company, valued at $2,706,294.64. This represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 2,000 shares of company stock valued at $125,930 in the last ninety days. 1.40% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

Several large investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd raised its stake in Prestige Consumer Healthcare by 312.5% during the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the period. UMB Bank n.a. grew its stake in shares of Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares during the period. Bayforest Capital Ltd acquired a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $29,000. First Horizon Corp purchased a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter valued at approximately $32,000. Finally, Barrow Hanley Mewhinney & Strauss LLC raised its position in shares of Prestige Consumer Healthcare by 106.8% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after buying an additional 283 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).